Previous Article | Next Article 
Infection and Immunity, June 2004, p. 3276-3283, Vol. 72, No. 6
0019-9567/04/$08.00+0 DOI: 10.1128/IAI.72.6.3276-3283.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Enhancement of Anthrax Lethal Toxin Cytotoxicity: a Subset of Monoclonal Antibodies against Protective Antigen Increases Lethal Toxin-Mediated Killing of Murine Macrophages
Nehal Mohamed,1* Juan Li,1 Claudia S. Ferreira,1 Stephen F. Little,2 Arthur M. Friedlander,2 George L. Spitalny,1 and Leslie S. Casey1
Elusys Therapeutics, Inc., Pine Brook, New Jersey 07058,1
U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 217022
Received 8 October 2003/
Returned for modification 3 December 2003/
Accepted 22 February 2004
We investigated the ability of using monoclonal antibodies (MAbs) against anthrax protective antigen (PA), an anthrax exotoxin component, to modulate exotoxin cytotoxic activity on target macrophage cell lines. Anthrax PA plays a critical role in the pathogenesis of Bacillus anthracis infection. PA is the cell-binding component of the two anthrax exotoxins: lethal toxin (LeTx) and edema toxin. Several MAbs that bind the PA component of LeTx are known to neutralize LeTx-mediated killing of target macrophages. Here we describe for the first time an overlooked population of anti-PA MAbs that, in contrast, function to increase the potency of LeTx against murine macrophage cell lines. The results support a possible mechanism of enhancement: binding of MAb to PA on the macrophage cell surface stabilizes the PA by interaction of MAb with macrophage Fc
receptors. This results in an increase in the amount of PA bound to the cell surface, which in turn leads to an enhancement in cell killing, most likely due to increased internalization of LF. Blocking of PA-receptor binding eliminates enhancement by MAb, demonstrating the importance of this step for the observed enhancement. The additional significance of these results is that, at least in mice, immunization with PA appears to elicit a poly-clonal response that has a significant prevalence of MAbs that enhance LeTx-mediated killing in macrophages.
* Corresponding author. Mailing address: Elusys Therapeutics, Inc., 10 Bloomfield Ave., Pine Brook, NJ 07058. Phone: (973) 808-0222. Fax: (973) 808-0322. E-mail:
Nmohamed{at}elusys.com.
Editor: J. T. Barbieri
Infection and Immunity, June 2004, p. 3276-3283, Vol. 72, No. 6
0019-9567/04/$08.00+0 DOI: 10.1128/IAI.72.6.3276-3283.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Kelly-Cirino, C. D., Mantis, N. J.
(2009). Neutralizing Monoclonal Antibodies Directed against Defined Linear Epitopes on Domain 4 of Anthrax Protective Antigen. Infect. Immun.
77: 4859-4867
[Abstract]
[Full Text]
-
Verma, A., Ngundi, M. M., Meade, B. D., De Pascalis, R., Elkins, K. L., Burns, D. L.
(2009). Analysis of the Fc Gamma Receptor-Dependent Component of Neutralization Measured by Anthrax Toxin Neutralization Assays. CVI
16: 1405-1412
[Abstract]
[Full Text]
-
He, X., Sun, X., Wang, J., Wang, X., Zhang, Q., Tzipori, S., Feng, H.
(2009). Antibody-Enhanced, Fc Gamma Receptor-Mediated Endocytosis of Clostridium difficile Toxin A. Infect. Immun.
77: 2294-2303
[Abstract]
[Full Text]
-
Abboud, N., Casadevall, A.
(2008). Immunogenicity of Bacillus anthracis Protective Antigen Domains and Efficacy of Elicited Antibody Responses Depend on Host Genetic Background. CVI
15: 1115-1123
[Abstract]
[Full Text]
-
Staats, H. F., Alam, S. M., Scearce, R. M., Kirwan, S. M., Zhang, J. X., Gwinn, W. M., Haynes, B. F.
(2007). In Vitro and In Vivo Characterization of Anthrax Anti-Protective Antigen and Anti-Lethal Factor Monoclonal Antibodies after Passive Transfer in a Mouse Lethal Toxin Challenge Model To Define Correlates of Immunity. Infect. Immun.
75: 5443-5452
[Abstract]
[Full Text]
-
Vitale, L., Blanset, D., Lowy, I., O'Neill, T., Goldstein, J., Little, S. F., Andrews, G. P., Dorough, G., Taylor, R. K., Keler, T.
(2006). Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity.. Infect. Immun.
74: 5840-5847
[Abstract]
[Full Text]
-
Rivera, J., Nakouzi, A., Abboud, N., Revskaya, E., Goldman, D., Collier, R. J., Dadachova, E., Casadevall, A.
(2006). A Monoclonal Antibody to Bacillus anthracis Protective Antigen Defines a Neutralizing Epitope in Domain 1. Infect. Immun.
74: 4149-4156
[Abstract]
[Full Text]
-
Hanson, J. F., Taft, S. C., Weiss, A. A.
(2006). Neutralizing Antibodies and Persistence of Immunity following Anthrax Vaccination. CVI
13: 208-213
[Abstract]
[Full Text]
-
Peterson, J. W., Comer, J. E., Noffsinger, D. M., Wenglikowski, A., Walberg, K. G., Chatuev, B. M., Chopra, A. K., Stanberry, L. R., Kang, A. S., Scholz, W. W., Sircar, J.
(2006). Human Monoclonal Anti-Protective Antigen Antibody Completely Protects Rabbits and Is Synergistic with Ciprofloxacin in Protecting Mice and Guinea Pigs against Inhalation Anthrax. Infect. Immun.
74: 1016-1024
[Abstract]
[Full Text]
-
Peachman, K. K., Rao, M., Alving, C. R., Burge, R., Leppla, S. H., Rao, V. B., Matyas, G. R.
(2006). Correlation between Lethal Toxin-Neutralizing Antibody Titers and Protection from Intranasal Challenge with Bacillus anthracis Ames Strain Spores in Mice after Transcutaneous Immunization with Recombinant Anthrax Protective Antigen. Infect. Immun.
74: 794-797
[Abstract]
[Full Text]
-
Laffly, E., Danjou, L., Condemine, F., Vidal, D., Drouet, E., Lefranc, M.-P., Bottex, C., Thullier, P.
(2005). Selection of a Macaque Fab with Framework Regions Like Those in Humans, High Affinity, and Ability To Neutralize the Protective Antigen (PA) of Bacillus anthracis by Binding to the Segment of PA between Residues 686 and 694. Antimicrob. Agents Chemother.
49: 3414-3420
[Abstract]
[Full Text]